Inhibition of EGFR with erlotinib attenuated the development of diabetic nephropathy in type 1 diabetes, which was mediated at least in part by inhibition of mTOR and activation of AMPK, with increased autophagy and inhibition of ER stress. Here, EGFR is linked to diabetic kidney disease.